FDA-approved fibrinogen concentrate FESILTY targets congenital fibrinogen deficiency with faster dosing and room-temperature storage.
Grifols (NASDAQ:GRFS) introduced FESILTY, a human-derived fibrinogen concentrate, for treating acute bleeding in patients with congenital fibrinogen deficiency. The therapy offers precise dosing without cross-matching, addressing a rare genetic condition affecting clotting proteins.
FESILTY received FDA approval based on Phase I/III clinical data confirming safety and efficacy. It outperforms traditional options like cryoprecipitate by enabling faster reconstitution and room-temperature storage, critical for time-sensitive bleeding events.
The product carries risks, including hypersensitivity and thrombotic events, and is contraindicated for patients with severe allergies to its components. Grifols, a global plasma-derived medicines provider, aims to expand treatment options for rare disorders.